Moreover, the idea of SMURF1 inhibition in patients has gained interest as a potential therapeutic strategy in other clinical contexts including pulmonary hypertension [23,24] and macular degeneration [25]. The gene discussed is SMURF1; the disease is pulmonary arterial hypertension.